PMID- 18160618
OWN - NLM
STAT- MEDLINE
DCOM- 20080416
LR  - 20220227
IS  - 1556-679X (Electronic)
IS  - 1556-6811 (Print)
IS  - 1556-679X (Linking)
VI  - 15
IP  - 3
DP  - 2008 Mar
TI  - Reduction of chemokine secretion in response to mycobacteria in 
      infliximab-treated patients.
PG  - 506-12
AB  - The use of anti-tumor necrosis factor (TNF) agents as a treatment for chronic 
      inflammatory conditions has been shown to be associated with an increased risk of 
      developing tuberculosis. We studied the effect of the anti-TNF antibody 
      infliximab on antimycobacterial immunity in 26 patients with rheumatoid arthritis 
      or ankylosing spondylitis by use of an in vitro whole-blood model employing a 
      reporter mycobacterium. Blood samples taken before and 30 min and 7 days after a 
      2-hour infliximab infusion were compared in terms of their abilities both to 
      suppress luminescence of Mycobacterium bovis bacillus Calmette-Guerin lux and to 
      secrete chemokines and cytokines 24 and 96 h after infection. No immediate effect 
      of infliximab on mycobacterial luminescence was detected using this bioassay, 
      irrespective of whether patients were receiving their first (n = 14) or 
      maintenance (n = 12) doses of infliximab. Moreover, no effect on mycobacterial 
      luminescence was detected when blood was taken 7 days after infliximab treatment 
      (n = 7). By contrast, there was a significant reduction in the chemokines 
      implicated in cellular trafficking, namely, interleukin-8, macrophage-inhibitory 
      protein-1alpha (MIP-1alpha), MIP-1beta (24 h and 96 h), and monocyte 
      chemoattractant protein-1 (MCP-1) (24 h) following BCG lux strain infection in 
      the 30-minute post-infliximab-infusion blood samples (P < 0.05). This effect was 
      sustained by MIP-1beta and MCP-1 (24 h; P < 0.05) at 7 days after infusion. Our 
      results suggest that the development of tuberculosis in infliximab-treated 
      patients is not directly related to the mycobactericidal effects of TNF but may 
      be due to inhibition of TNF-dependent chemokine gradients disrupting cellular 
      migration necessary to maintain the integrity of the granuloma.
FAU - Newton, Sandra M
AU  - Newton SM
AD  - Wellcome Trust Centre for Clinical Tropical Medicine and Department of 
      Paediatrics, Imperial College London, Wright Fleming Institute, United Kingdom.
FAU - Mackie, Sarah L
AU  - Mackie SL
FAU - Martineau, Adrian R
AU  - Martineau AR
FAU - Wilkinson, Katalin A
AU  - Wilkinson KA
FAU - Kampmann, Beate
AU  - Kampmann B
FAU - Fisher, Corinne
AU  - Fisher C
FAU - Dutta, Shouma
AU  - Dutta S
FAU - Levin, Michael
AU  - Levin M
FAU - Wilkinson, Robert J
AU  - Wilkinson RJ
FAU - Pasvol, Geoffrey
AU  - Pasvol G
LA  - eng
GR  - GR077273MA/WT_/Wellcome Trust/United Kingdom
GR  - 060079/WT_/Wellcome Trust/United Kingdom
GR  - 077273/WT_/Wellcome Trust/United Kingdom
GR  - 064261/WT_/Wellcome Trust/United Kingdom
GR  - MC_U117588499/MRC_/Medical Research Council/United Kingdom
GR  - 072070/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071226
PL  - United States
TA  - Clin Vaccine Immunol
JT  - Clinical and vaccine immunology : CVI
JID - 101252125
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Chemokines)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antirheumatic Agents/pharmacology/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/immunology/microbiology
MH  - Bacterial Proteins/genetics/metabolism
MH  - Biological Assay
MH  - Chemokines/*blood/drug effects
MH  - *Down-Regulation
MH  - Humans
MH  - Infliximab
MH  - Luminescence
MH  - Middle Aged
MH  - Mycobacterium bovis/genetics/*metabolism
MH  - Spondylitis, Ankylosing/*drug therapy/immunology/microbiology
MH  - Tuberculosis/immunology/microbiology
MH  - Tumor Necrosis Factor-alpha
PMC - PMC2268261
EDAT- 2007/12/28 09:00
MHDA- 2008/04/17 09:00
PMCR- 2008/09/01
CRDT- 2007/12/28 09:00
PHST- 2007/12/28 09:00 [pubmed]
PHST- 2008/04/17 09:00 [medline]
PHST- 2007/12/28 09:00 [entrez]
PHST- 2008/09/01 00:00 [pmc-release]
AID - CVI.00401-07 [pii]
AID - 0401-07 [pii]
AID - 10.1128/CVI.00401-07 [doi]
PST - ppublish
SO  - Clin Vaccine Immunol. 2008 Mar;15(3):506-12. doi: 10.1128/CVI.00401-07. Epub 2007 
      Dec 26.